人工肝联合磷甲酸钠治疗重型肝炎30例分析  

Artificial liver union phosphorus sodium formiate sodium formate treatment heavy hepatitis 30 examples analyses

作　　者：王锦华 汤建红 许让贤 贾红宇 Wang Jinhua, Tang Jianhong, Xu Rangxian, Jia Hongyu

机构地区：浙江省长兴县中医院,313100

出　　处：《中外健康文摘：临床医师》2007年第9期100-101,共2页

摘　　要：目的：观察人工肝联合磷甲酸钠对重型肝炎的治疗效果。方法：采用单重血浆置换疗法治疗30例重型肝炎,3～5天进行一次,共98例次。同时给予磷甲酸钠3.0克/天静滴,28～56天;并取患者治疗前后静脉血做血生化和病毒学检测行自身对照分析。结果：人工肝联合磷甲酸钠治疗后血清TBil、HBsAg、HBeAg含量明显下降,差异有显著性（P〈0.01）。磷甲酸钠疗程结束后,HBeAg和（或）HBV-DNA阴转率53.3%。结论：人工肝联合磷甲酸钠可作为治疗早中期重型肝炎的有效方法。Objective： Observes the artificial liver union phosphorus sodium formiate sodium formate to the heavy hepatitis treatment result. Method： Uses common substance the blood plasma replacement therapy to treat 30 examples heavy hepatitises, the 3-5 day carries on a time, altogether 98 examples. Simultaneously gives the phosphorus sodium formiate sodium formate 3.0 gram/day static drops, the 28-56 day; Around and takes the patient to treat venous blood makes the blood biochemistry and the virology examination line of own check analysis. Finally： After the artificial liver union phosphorus sodium formiate sodium formate treatment blood serum TBil, HBsAg, the HBeAg content obviously drops, the difference has significance（P〈0.01）. After the phosphorus sodium formiate sodium formate treatment course had ended, HBeAg and （or） HBV--DNA cloudy rate of rotation 53.3%. Conclusion： The artificial liver union phosphorus sodium formiate sodium formate may take treats the early intermediate stage heavy hepatitis the effective method.

关 键 词：人工肝 磷甲酸钠 重型肝炎 

分 类 号：R512.6[医药卫生—临床医学;医药卫生—内科学]